Berg Biosystems focuses our research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Interrogative Biology^TM discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg Biosystems is poised to realize its pursuit of a healthier tomorrow.